Abivax aims to set cancer concerns with ulcerative colitis drug to rest

Marc de Garidel, Abivax CEO June 30, 2026 11:38 AM EDTUpdated 01:11 PM R&D Abi­vax aims to set can­cer con­cerns with ul­cer­a­tive col­i­tis drug to rest Elizabeth Cairns Senior biopharma journalist Late on Mon­day, Abi­vax re­leased new tri­al da­ta on its ul­cer­a­tive col­i­tis can­di­date, show­ing that can­cer cas­es in a Phase 3 tri­al were with­in the … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER